Their expression and prognosis in the four types of breast cancer were observed separately, and the results showed that FBN2, MEX3A, and TPD52 were more expressed in luminal A, HER2, and TPD52 than in normal samples. This evidence concerns the gene ERBB2 and breast carcinoma.